Singapore, 11 June 2021 – A team of researchers from National Neuroscience Institute (NNI), National University of Singapore (NUS) and Duke-NUS Medical School (Duke-NUS) are studying new drug targets for the treatment of glioblastoma (GBM). The team received a grant under the Open Fund Large Collaborative Grant (MOH-000541), which is supported by the National Research Foundation Singapore and administered by the Singapore Ministry of Health’s National Medical Research Council.
Glioblastoma is a brutal form of cancer because it spreads quickly in the brain and is difficult to treat. Common symptoms include severe headaches, seizures, personality changes and confusion (impaired cognition) which can be distressing for patients and their family members.
“A glioblastoma diagnosis is particularly grim, because even with the current standard of care, recurrence is the rule rather than the exception. This generous funding gives us an opportunity to address the many challenges posed by this aggressive tumour, opening up the possibility of better diagnostics and treatment avenues directed at specific groups of patients,” explained Associate Professor Ang Beng Ti, Head and Senior Consultant, Department of Neurosurgery, NNI @ Singapore General Hospital campus and the project’s Principal Investigator.
NNI sees close to 100 new cases of glioblastoma every year. Although
Article originally posted at